Clinical trialsCompany release

ProKidney Keeps PROACT 1 eGFR Slope Readout on Track for Q2 2027

🇺🇸 Prokidney Corp. (PROK) · Thu 12 Nov 2026

The US company says enrolment in its Phase 3 rilparencel trial will exceed 500 patients, while cash of $141.9 million funds operations into mid-2027.

ProKidney reported third-quarter 2026 results on 12 November, saying its pivotal Phase 3 PROACT 1 trial (REGEN-006) remains on track to deliver eGFR slope topline data in the second quarter of 2027. The study is testing rilparencel in patients with advanced chronic kidney disease (CKD) and type 2 diabetes.

The company expects to complete enrolment for the confirmatory analysis in the first quarter of 2027. It now anticipates more than 500 patients, an increase from the 470 previously planned.

On finances, cash fell to $141.9 million, which ProKidney says is enough to fund operations into mid-2027. That runway is only slightly beyond the expected timing of the topline readout. The quarterly net loss widened to $51.8 million.

The summary provided does not give further detail on the trial design, the comparator, the regulatory pathway or the reasons for the larger enrolment target.

What it means for your team

  • Regulatory teams tracking cell-based therapies in CKD should note that the eGFR slope topline is guided for Q2 2027, with enrolment for the confirmatory analysis closing in Q1 2027.
  • The increase in the confirmatory cohort to over 500 patients from 470 is a change to watch for how it may affect the data package supporting any future filing.
  • Market-access teams should note that the company's stated cash runway into mid-2027 sits close to the readout window, so financing or partnering news may follow.

Company's press release (SEC filing): Prokidney Corp. ↗

Article written by VigiEye from the official source (Prokidney Corp.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →